The late news on baff in autoimmune diseases

Autoimmunity Reviews

Volumn 9, Issue 12, 2010, Pages 804-806

  Youinou, Pierre ^a,b   Pers, Jacques Olivier ^a,b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CYTOKINE; TRANSCRIPTION FACTOR;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL SURVIVAL; CELLULAR IMMUNITY; HUMAN; IMMUNOREGULATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN VARIANT; REVIEW; T LYMPHOCYTE;

ALTERNATIVE SPLICING; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; FEEDBACK, PHYSIOLOGICAL; HOMEOSTASIS; HUMANS; PROTEIN ISOFORMS;

EID: 77956924542     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.06.011     Document Type: Review

References (43)

1. Varin M.M., Le Pottier L., Youinou P., Saulep D., Mackay F., Pers J.O. B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF. Autoimmun Rev 2010, 9:604-608.
2. Daridon C., Youinou P., Pers J.O. BAFF, APRIL, TWE-PRIL: who's who?. Autoimmun Rev 2008, 7:267-271.
3. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
4. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
5. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002, 109:59-68.
6. Rochas C., Hillion S., Saraux A., Mageed R.A., Youinou P., Jamin C., et al. Transmembrane BAFF from rheumatoid synoviocytes requires IL-6 to induce the expression of RAG in B lymphocytes. Arthritis Rheum 2009, 60:1261-1271.
7. Eisenberg R. Why can't we find a new treatment for SLE?. J Autoimmun 2009, 32:223-230.
8. Toubi E., Shoenfeld Y. BLyS/BAFF: a potential target in the treatment of active SLE. Isr Med Assoc J 2004, 6:99-102.
9. Mackay F., Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009, 9:491-502.
10. Daridon C., Devauchelle V., Hutin P., Le Berre R., Martins-Carvalho C., Bendaoud B., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007, 56:1134-1144.
11. Mackay F., Schneider P., Rennert P., Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
12. George-Chandy A., Trysberg E., Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008, 10:R97.
13. Bosello S., Youinou P., Daridon C., Tolusso B., Bendaoud B., Pietrapertosa D., et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008, 35:1256-1264.
14. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003, 62:168-171.
15. Collins C.E., Gavin A.L., Migone T.S., Hilbert D.M., Nemazee D., Stohl W. BLyS isoforms in SLE: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006, 8:R6.
16. Carter R.H., Zhao H., Liu X., Pelletier M., Chatham W., Kimberly R., et al. Expression and occupancy of BAFF-R on B cells in SLE. Arthritis Rheum 2005, 52:3943-3954.
17. Gao H., Bian A., Zheng Y., Li R., Ji Q., Huang G., et al. sBAFF mutants induce neutralizing antibodies against BAFF. FEBS Lett 2007, 581:581-586.
18. Le Pottier L., Bendaoud B., Dueymes M., Daridon C., Youinou P., Shoenfeld Y., et al. BAFF, a new target for IVIg in autoimmunity and cancer. J Clin Immunol 2007, 27:257-265.
19. Le Pottier L., Bendaoud B., Renaudineau Y., Youinou P., Pers J.O., Daridon C. New ELISA for B cell-activating factor. Clin Chem 2009, 55:1843-1851.
20. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453-1466.
21. Schneider P., Takatsuka H., Wilson A., Mackay F., Tardivel A., Lens S., et al. Maturation of marginal zone and follicular B cells requires BAFF and is independent of B cell maturation antigen. J Exp Med 2001, 194:1691-1697.
22. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
23. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
24. Le Pottier L., Devauchelle V., Fautrel A., Daridon C., Saraux A., Youinou P., et al. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 2009, 182:3540-3547.
25. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829.
26. Batten M., Fletcher C., Ng L.G., Groom J., Wheway J., Laâbi Y., et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004, 172:812-822.
27. Yoshimoto K., Takahashi Y., Ogasawara M., Setoyama Y., Suzuki K., Tsuzaka K., et al. Aberrant expression of BAFF in T cells of SLE, which is recapitulated by a human T cell line. Int Immunol 2006, 18:1189-1196.
28. Lai Kwan Lam Q., King Hung Ko O., Zheng B.J., Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci USA 2008, 105:14993-14998.
29. Sutherland A.P., Ng L.G., Fletcher C.A., Shum B., Newton R.A., Grey S.T., et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005, 174:5537-5544.
30. Walters S., Webster K.E., Sutherland A., Gardam S., Groom J., Liuwantara D., et al. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol 2009, 182:793-801.
31. Krumbholz M., Theil D., Derfuss T., Rosenwald A., Schrader F., Monoranu C.M., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005, 201:195-200.
32. Ragheb S., Lisak R., Lewis R., Van Stavern G., Gonzales F., Simon K. A potential role for BAFF in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 2008, 65:1358-1362.
33. Krumbholz M., Faber H., Steinmeyer F., Hoffmann L.A., Kümpfel T., Pellkofer H., et al. IFN-B increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008, 131:1455-1463.
34. Hamzaoui K., Houman H., Hentati F., Hamzaoui A. BAFF is up-regulated in central nervous system of neuro-Behçet's disease. J Neuroimmunol 2008, 200:111-114.
35. Crupi R., Cambiaghi M., Spatz L., Hen R., Thorn M., Friedman E., et al. Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice. Biol Psychiatry 2010, 67:558-566.
36. Gavin A.L., Aït-Azzouzene D., Ware C.F., Nemazee D. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003, 278:38220-38228.
37. Gavin A.L., Duong B., Skog P., Aït-Azzouzene D., Greaves D.R., Scott M.L., et al. DeltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 2005, 175:319-328.
38. Lin-Lee Y.C., Pham L.V., Tamayo A.T., Fu L., Zhou H.J., Yoshimura L.C., et al. Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem 2006, 281:18878-18887.
39. Kovács L., Szodoray P., Kiss E. Secondary tumours in Sjögren's syndrome. Autoimmun Rev. 2010, 9:203-206.
40. Tobón G.J., Pers J.O., Youinou P., Saraux A. B cell-targeted therapies in Sjögren's syndrome. Autoimmun Rev 2010, 9:224-228.
41. Cornec D., Avouac J., Youinou P., Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009, 8:515-519.
42. Jacobi A.M., Huang W., Wang T., Freimuth W., Sanz I., Furie R., et al. Effect of long-term belimumab treatment on B cells in SLE: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010, 62:201-210.
43. Pelletier M., Thompson J.S., Qian F., Bixler S.A., Gong D., Cachero T., et al. Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem 2003, 278:33127-33133.